Polyenes

Dec 06, 2017

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience®

Oct 27, 2017

Global Natamycin Market - Growth, Trends and Forecasts (2017-2022) - Research and Markets

Jul 25, 2017

Eisai Submits Supplemental New Drug Application to FDA for Lenvatinib in First-Line Hepatocellular Carcinoma

Jun 04, 2017

Lenvatinib Demonstrates Positive Results vs Sorafenib Across All Endpoints in First-Line Phase 3 Non-inferiority Trial of Unresectable Hepatocellular Carcinoma (uHCC)

Jun 03, 2017

Further Study of Combination of Eisai's Lenvatinib and Merck's Pembrolizumab in Previously Treated Patients with Metastatic Endometrial Cancer Supported by Interim Analysis of Ongoing Phase 1b/2 Trial